Handok will be reborn as health innovator

Published: 2009-01-22 06:58:00

Updated: 2009-01-22 06:58:00

Under the spirit of ‘The Health Innovator’ this year despite economic downturn, Handok will continue to expand its presence in the domestic market through joint development of new products and licensing with advanced pharmaceutical and bio-venture companies in Japan, Europe and the United States,...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK